Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 14Gynecologic 7Gastrointestinal 5Other solid neoplasm 3CNS 3Breast 3Other hematologic neoplasm 2Genitourinary 2Sarcoma 1NET 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Recurrence 1Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Radiotherapy 137Cyclophosphamide 132Temozolomide 116Doxorubicin 99Filgrastim 68Ifosfamide 64Gemcitabine 58Etoposide 55Bevacizumab 51Imatinib Mesylate 50fludarabine phosphate 49Irinotecan 46pembrolizumab 45Peripheral Blood Stem Cell Transplantation 45pazopanib 43Magnetic Resonance Spectroscopy 42Methotrexate 40Carboplatin 40Busulfan 40Vincristine 38Surgical Procedures, Operative 37Nivolumab 37Melphalan 37Cisplatin 36Radiation 34Blood Specimen Collection 33Mycophenolic Acid 31Cyclosporine 31Docetaxel 29Trabectedin 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × nintedanib × Sarcoma × Clear all
NCT01380782 2014-08-18

BIBF 1120 for Recurrent High-Grade Gliomas

Dana-Farber Cancer Institute

Phase 2 Completed
37 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Recurrence, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡